Landmark Research Studies
completed

OASIS 4, a phase III, double-blind, parallel group randomized clinical trial, evaluated the efficacy and safety of clopidogrel when given with aspirin patients with non- ST-segment elevation acute coronary syndromes (ACS).

Clopidogrel had benefits; however, there was an increased risk of major bleeding.

The findings of the OASIS 4 CURE trial led to widespread use of clopidogrel in non -ST segment elevation ACS patients, modification of practice guidelines and regulatory approvals in many countries around the world.

Clopidogrel has become an established therapy in these patients and one of the most commonly used drugs in ACS.

Study Type

Interventional - Drug

Study Design

Double-blind parallel group RCT

NO. of Countries

28

NO. of Sites

482

NO. of Participants

12562

Study Period

1998-2001

Sponsor

Sanofi

Sanofi

Back To Top